Modest 2% CAGR Anticipated in Urinary Tract Infection (UTI) Treatment Market Revenues from 2019 to 2029

The increasing prevalence of Urinary Tract Infection (UTI) and the growth in the number of prescriptions of quinolone antibiotics are expected to fuel the growth of the Urinary Tract Infection Treatment Market. According to a new study published by Future Market Insights (FMI), the global urinary tract infection treatment market revenues will grow at a mere 2% CAGR between 2019 and 2029.

Launch of New Antibiotics for Bacterial Infections to Sustain Revenues

An increase in the number of research and development initiatives for developing novel therapeutics has led to the launch of new drugs into the urinary tract infection treatment market. Manufacturers are currently focusing on expanding their pipeline portfolio for the treatment of bacterial infections. Moreover, regulatory bodies such as FDA have accelerated the approval process of drugs.

Request a Sample Report with Table of Contents and Figures: https://www.futuremarketinsights.com/reports/sample/rep-gb-1340

Recently, in August 2018, Melinta Therapeutics announced the launch of Vabomere (meropenem and vaborbactam) for patients who require treatment for complicated urinary tract infections. Similarly, one more drug has been approved by FDA in June 2018, Zemdri by Achaogen, Inc., for the treatment of adults suffering from Complicated Urinary Tract infections (cUTI). An increase in the launch and approval of novel therapeutics for the treatment of bacterial infections is expected to contribute to the growth of the urinary tract infection treatment market.

Quinolones, the broad-spectrum antibiotics effective against a wide range of bacterial diseases, have a bactericidal activity that enables them to penetrate deep into the tissue. Their excellent bioavailability is a plus point. In addition, they have favorable tolerability and safety profile. Moreover, they have significant antimicrobial activity. Thus, quinolones are most preferred for the treatment of urinary tract infections. Some of the widely used quinolones for the prevention of bacterial infection include ciprofloxacin (Cipro), ofloxacin (Floxin), norfloxacin (Noroxin), and others. Quinolones are mostly favored over trimethoprim-sulfamethoxazole (TMP-SMX) for the treatment of uncomplicated urinary tract infections owing to the increasing resistance of bacteria towards antibiotics such as trimethoprim-sulfamethoxazole, beta-lactam antibiotics, and others

Europe Remains a Major Revenue Contributor

Europe holds a considerable revenue share in the UTI treatment market. The rising prevalence of urinary tract infections among the population and increasing hospital visits are among the factors that are likely to propel the growth of the urinary tract infection treatment market. It is estimated that the urinary tract infection treatment market will create an incremental $ opportunity worth nearly US$ 9 Mn between 2019 and 2029. Quinolones are anticipated to boost the growth of the urinary tract infection treatment market owing to the increasing prescription and high effectiveness as antimicrobial antibiotics.

Methodology Insights Await! Request Now! @
https://www.futuremarketinsights.com/request-report-methodology/rep-gb-1340

Demand from Retail Pharmacies to Register High Growth

The global urinary tract infection treatment market has been segmented on the basis of drug class, indication, and distribution channel. On the basis of drug class, the urinary tract infection treatment market has been segmented into Penicillin & Combinations, Quinolones, Cephalosporin, Aminoglycoside Antibiotics, Sulphonamides (Sulfamethoxazole +Trimethoprim), Azoles and Amphotericin B, Tetracycline (Doxycycline), Nitrofurans (Nitrofurantoin), and others. In terms of revenue, the quinolones segment is expected to hold a major share of the urinary tract infection treatment market during the forecast period since it is widely prescribed and has proven to be safe and effective for antimicrobial use.

Based on indication, the urinary tract infection treatment market has been segmented into complicated urinary tract infections and uncomplicated urinary tract infections. On the basis of distribution channels, the urinary tract infection treatment market has been categorized into hospital pharmacies, gynecology & urology clinics, drug stores, retail pharmacies, and online drug stores. The retail pharmacies segment is expected to exhibit high revenue growth in the urinary tract infection treatment market owing to the easy availability of antibiotics.

Key Companies in Urinary Tract Infection Treatment Market

The report studies some of the key companies operating in the urinary tract infection treatment market, such as Bayer AG, GlaxoSmithKline Pharmaceuticals Ltd., Pfizer, Allergan Plc, Almirall SA, Bristol-Myers Squibb, and Merck & Co., Inc. For more insights on the competitive landscape and other facets shaping the growth of the UTI treatment market.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, Stevie Award - recipient market research organization, and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel, and End Use over the next 10 years.

Contact Us:          

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Read Full Report, Stay Updated @
https://www.futuremarketinsights.com/reports/urinary-tract-infections-market

This release was published on openPR.